The use of β-blockers (BB) in heart failure (HF) has been considered a contradiction for
many years. Considering HF simply as a state of inadequate systolic function, BB were …

The introduction of beta-blockers in the treatment of cardiovascular diseases was a
milestone and one of the most important contributions to clinical medicine in the 20th …

Current heart failure guidelines mandate the use of β-blockers in patients with symptomatic
systolic heart failure. In the past 12–18 months, there have been several reported advances …

There is now considerable clinical trial data to support the use of β-blockers in patients with
congestive heart failure (CHF) due to systolic left ventricular dysfunction. A substantial …

Unfortunately, medical treatment remains largely a matter of opinion rather than of fact.
Treatment according to theoretical principles has at least two major flaws. First, if the …

For a long time beta-blockers were considered contraindicated for use in heart failure
although some experimental and clinical data already in the 1960s and 1970s suggested a …

Enhanced and sustained cardiac adrenergic drive occurs in heart failure and contributes, in
part, to the progression of left ventricular (LV) dysfunction and remodeling that are …

Enhanced and sustained cardiac adrenergic drive occurs in heart failure (HF) and
contributes, in part, to the progression of left ventricular (LV) dysfunction and remodeling that …

Systolic dysfunction and heart failure are major public health problems associated with a
significant risk of morbidity and mortality. During the past 2 decades, considerable progress …

ContextCare of patients with heart failure has been revolutionized throughout the past
decade. A paradigm shift in the strategy for treating heart failure caused by systolic …